Source study found

Story checked

Fontan circulation linked to accelerated biological aging in youth (opens in a new tab)

news-medical.net · 2026-10-06

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

4 supported
1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail

The story

Fontan circulation linked to accelerated biological aging in youth

news-medical.net · 2026-10-06

The story’s checkable claims.

Read the original story

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

4 supported
1 not covered

Open claim evidence

The source study

Accelerated Aging Fontan Phenotype Is Associated With Systemic Right Ventricles and Adverse Hemodynamics

Journal of the American Heart Association · 2026

Open source record Open in Tessa

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

Reading mode

Scan verdicts. Open evidence only when needed.

Browse by verdict

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredA Stanford Cardiovascular Institute team compared 90 children and adults with Fontan circulation with 59 people with normal heart structure and function, and published the study in the Journal of the American Heart Association.View evidenceHide evidence

As stated90 vs 59 participants

Why this verdict

The abstract-level profile supports the case-control comparison and sample sizes: Fontan patients N=90 and controls N=59. However, the supplied paper profile does not verify the Stanford Cardiovascular Institute attribution or publication venue, so the full claim is not fully verifiable at this evidence depth.

Study evidence

Patients with a Fontan circulation had shorter leukocyte telomere length than controls, consistent with accelerated biological aging.Median T/S ratio 1.04 (IQR 0.96–1.14) in Fontan vs 1.13 (IQR 0.96–1.24) in controls; P = 0.021.

“In this case-control study, we compared the telomere lengths of patients with Fontan circulation with controls”

Claim 2 of 5SupportedThe researchers found that people with Fontan circulation had shorter telomeres in white blood cells than the comparison group, with differences apparent even at young ages, pointing to signs of accelerated biological aging.View evidenceHide evidence

Why this verdict

The profile reports that leukocyte telomere length was shorter in Fontan patients than controls, measured by qPCR, with median T/S 1.04 vs 1.13 and P=0.021. The paper interprets this as consistent with an accelerated biological aging phenotype. The profile also reports adolescent/young adult median ages around 15 years, supporting the story’s framing that differences were apparent at young ages.

Study evidence

“In this case-control study, we compared the telomere lengths of patients with Fontan circulation with controls”

Claim 3 of 5SupportedThe telomere-shortening pattern was more pronounced in patients whose right ventricle served as the main pump, and shorter telomeres were associated with less favorable circulation measurements and lower oxygen levels in blood returning from the upper body.View evidenceHide evidence

Why this verdict

The profile reports within-Fontan associations between shorter telomeres and systemic right ventricle status, lower superior vena cava saturation, lower cardiac index, and higher systemic vascular resistance. The story frames these as associations rather than causal effects, which matches the abstract-level evidence.

Study evidence

Within the Fontan cohort (N=90), patients with a systemic right ventricle had shorter leukocyte telomere length: T/S ratio 1.02 (IQR 0.93–1.08) versus 1.05 (IQR 1.00–1.17); P=0.047.T/S 1.02 vs 1.05 (IQRs reported); P=0.047

“Patients with systemic right ventricles had shorter telomeres...; P=0.047”

Claim 4 of 5SupportedAt follow-up about a year later, nearly half of the patients with telomere loss had an increase in associated health conditions, compared with about one in five among those whose telomeres remained stable or lengthened.View evidenceHide evidence

As statednearly half vs about one in five

Why this verdict

The profile reports median follow-up of 13.07 months and that 46.7% of patients with telomere loss greater than 50 bp/year had increased comorbidities versus 20.5% among those with no telomere loss or telomere gain, P<0.001. The story’s 'nearly half' versus 'about one in five' framing accurately reflects these abstract data.

Study evidence

Patients with accelerated telomere loss (>50 bp loss/year) had a higher proportion with increased comorbidities at median 13.07 months follow-up compared with those without telomere loss.Risk difference ~26.2 percentage points (46.7% vs 20.5%); P<0.001

“At a median follow-up of 13.07 months, 46.7% of patients with telomere loss (>50 bp loss/y) experienced an increase in comorbidities”

Claim 5 of 5SupportedThe article says the study could not determine whether telomere shortening contributes to health problems or results from them, and it did not establish that telomere length predicts survival or the need for a heart transplant.View evidenceHide evidence

Why this verdict

The profile identifies the study as observational and notes that causal inference is limited, supporting the caveat that the study could not determine whether telomere shortening contributes to health problems or results from them. The profile reports short-term comorbidity outcomes, not survival or transplant prediction, so the statement that the study did not establish prediction of survival or heart transplant need is consistent with the supplied abstract-level profile.

Study evidence

“In this case-control study, we compared the telomere lengths of patients with Fontan circulation with controls”

Study evidence

“At a median follow-up of 13.07 months, 46.7% of patients with telomere loss (>50 bp loss/y) experienced an increase in comorbidities”

Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

Measurement method: leukocyte telomere length was measured by quantitative PCR and expressed as a relative T/S ratio.
The story mentions leukocyte/white-blood-cell telomeres but does not describe the qPCR T/S measurement method or assay-specific limitations. This is a methodological detail relevant to interpretation but not central to the story’s main causal caveat.
From Case-control observational study

6 things the story did carry across

Case-control observational comparison of leukocyte telomere length in Fontan patients versus controls, with Fontan N=90 and controls N=59.
Primary finding: Fontan patients had shorter leukocyte telomeres than controls, consistent with an accelerated biological aging phenotype.
Within-Fontan associations: shorter telomeres were associated with systemic right ventricle anatomy and adverse hemodynamics, including lower superior vena cava saturation, lower cardiac index, and higher systemic vascular resistance.
Longitudinal component: at median 13.07 months, telomere loss greater than 50 bp/year was associated with higher incidence of increased comorbidities, 46.7% vs 20.5%.
Causal inference is limited by the observational case-control and longitudinal designs; associations do not establish that Fontan physiology causes telomere shortening or that telomere loss causes comorbidity increases.
The abstract-level profile does not establish long-term outcomes such as survival or heart transplant need, and the median follow-up was only about 13 months.

Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoDetermine whether individuals with a Fontan circulation exhibit accelerated biological aging, assessed by shorter leukocyte telomere length compared with controls.Case-control observational studyExpand

In plain English

In a case-control study, individuals with a Fontan circulation had shorter leukocyte telomere length, measured by qPCR (telomeric DNA to single-copy gene ratio), than control participants, consistent with an accelerated biological aging phenotype.

Key findings

Patients with a Fontan circulation had shorter leukocyte telomere length than controls, consistent with accelerated biological aging.Median T/S ratio 1.04 (IQR 0.96–1.14) in Fontan vs 1.13 (IQR 0.96–1.24) in controls; P = 0.021.

“In this case-control study, we compared the telomere lengths of patients with Fontan circulation with controls”

What this piece can’t prove

Case-control observational design limits causal inference about Fontan physiology causing telomere shortening.
Abstract provides limited methodological detail (e.g., assay calibration, covariate adjustment, selection/matching of controls) required to fully assess bias and confounding.
Follow-up for comorbidity progression reported as median 13.07 months (short-term), limiting inference about long-term clinical consequences of telomere changes.

2human in vivoIdentify Fontan-specific anatomical/physiologic factors (systemic right ventricle and adverse hemodynamics) associated with shorter telomere length within the Fontan cohort.Within-cohort observational associationsExpand

In plain English

Within a Fontan cohort (N=90), shorter leukocyte telomere length (qPCR T/S ratio) was associated with having a systemic right ventricle and with adverse hemodynamic measures: lower superior vena cava saturation, lower cardiac index, and higher systemic vascular resistance. Associations are reported as subgroup comparison for ventricular morphology and as regression coefficients (β) with 95% CIs and P values for hemodynamic variables.

Key findings

Within the Fontan cohort (N=90), patients with a systemic right ventricle had shorter leukocyte telomere length: T/S ratio 1.02 (IQR 0.93–1.08) versus 1.05 (IQR 1.00–1.17); P=0.047.T/S 1.02 vs 1.05 (IQRs reported); P=0.047
Lower superior vena cava saturation was associated with shorter telomeres (regression β=0.007 per unit increase in SVC saturation; 95% CI 0.002–0.012; P=0.013).β=0.007 (95% CI 0.002–0.012); P=0.013

“Patients with systemic right ventricles had shorter telomeres...; P=0.047”

What this piece can’t prove

Sample size is modest (N=90) for within-cohort subgroup and multivariable analyses.
Cross-sectional associations reported for anatomy and hemodynamics limit causal inference.

2 further details could not be confirmed from the summary.

3human in vivoAssess whether accelerated telomere loss over follow-up is associated with increased comorbidity burden in Fontan patients.Longitudinal observational follow-upExpand

In plain English

In a longitudinal component of the study (median follow-up 13.07 months), Fontan patients with accelerated telomere loss (>50 bp loss/year) experienced a higher proportion of increased comorbidity burden compared with patients who had no telomere shortening or an increase in telomere length.

Key findings

Patients with accelerated telomere loss (>50 bp loss/year) had a higher proportion with increased comorbidities at median 13.07 months follow-up compared with those without telomere loss.Risk difference ~26.2 percentage points (46.7% vs 20.5%); P<0.001

“At a median follow-up of 13.07 months, 46.7% of patients with telomere loss (>50 bp loss/y) experienced an increase in comorbidities”

What this piece can’t prove

Abstract provides limited methodological detail for the longitudinal analysis (no subgroup counts, no definition of comorbidity outcome, and no description of adjustment for confounding).
Short median follow-up (13.07 months) may limit assessment of longer-term comorbidity accrual.
Observational design precludes causal inference between telomere loss and increases in comorbidity; temporal ordering is supported by serial telomere measurement but residual confounding is possible.

Finally, the search trail

Method layer